Publications

Asterisks (*) delineate equal contribution. Bold face: members of the group when work was executed.

• Meyer M, Parpoulas C, Barthelemy T, Becker JP, Charoentong P, Lyu Y, Borsig S, Bulbuc N, Tessmer C, Weinacht L, Ibberson D, Schmidt P, Pipkorn R, Eichmüller SB, Steinberger P, Lindner K, Poschke I, Platten M, Fröhling S, Riemer AB, Hassel JC, Roberti MP, Jäger D, Zörnig I, and Momburg F (2024) MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection. Front Immunol 14: 1294565. Link to full text

• Kordaß T, Chao T-Y, Osen W, and Eichmüller SB (2023) Novel microRNAs modulating ecto-5′-nucleotidase expression. Front. Immunol. 14. Link to full text
• Pane AA, Kordaß T, Hotz-Wagenblatt A, Dickes E, Kopp-Schneider A, Will R, Seliger B, Osen W, and Eichmüller SB (2023) miRNAs affecting the susceptibility of melanoma cells to CD8+ T cell-mediated cytolysis. Clin Transl Med 13(2): e1186. Link to full text
• Chao T-Y*, Kordaß T*, Osen W, and Eichmüller SB (2022) SOX9 is a target of miR-134-3p and miR-224-3p in breast cancer cell lines. Mol Cell Biochem 478(2):305-315. Link to full text

• Hartmann L, Osen W, Eichmüller OL, Kordaß T, Furkel J, Dickes E, Reid C, Debus J, Brons S, Abdollahi A, Moustafa M, Rieken S, and Eichmüller SB (2022) Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model. Cancer Lett. 500. Link to full text
• Kehl N, Kilian M, Michel J, Wagner TR, Uhrig S, Brobeil A, Sester LS, Blobner S, Steiger S, Hundemer M, Weinhold N, Rippe K, Fröhling S, Eichmüller SB, Bunse L, Müller-Tidow C, Goldschmidt H, Platten M, Raab MS, and Friedrich M (2022) IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells. Journal for ImmunoTherapy for Cancer 10. Link to full text
• Kustermann M, Dasari P, Knape I, Keltsch E, Liu J, Pfluger S, Osen W, Holzmann K, Huber-Lang M, Debatin KM, and Strauss G (2022) Adoptively Transferred in vitro-Generated Myeloid-Derived Suppressor Cells Improve T-Cell Function and Antigen-Specific Immunity after Traumatic Lung Injury. J Innate Immun 1-18.
• Hernández-Malmierca P, Vonficht D, Schnell A, Uckelmann HJ, Bollhagen A, Mahmoud MAA, Landua SL, Salm EVd, Trautmann CL, Raffel S, Grünschläger F, Lutz R, Ghosh M, Renders S, Correia N, Donato E, Dixon KO, Hirche C, Andresen C, Robens C, Werner PS, Boch T, Eisel D, Osen W, Pilz F, Przybylla A, Klein C, Buchholz F, Milsom MD, Essers MAG, Eichmüller SB, Hofmann W-K, Nowak D, Hübschmann D, Hundemer M, Thiede C, Bullinger L, Müller-Tidow C, Armstrong SA, Trumpp A, Kuchroo VK, and Haas S (2022) Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. Cell Stem Cell 29(5):760-75 e10 doi: 10.1016/j.stem.2022.04.007.
• Kilian M, Friedrich M, Sanghvi K, Green E, Pusch S, Kawauchi D, Löwer M, Sonner JK, Krämer C, Zaman J, Jung S, Breckwoldt MO, Willimsky G, Eichmüller SB, Deimling Av, Wick W, Sahm F, Platten M, and Bunse L (2022) T cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas. Clin Cancer Res 28:378-389.

• Horak P et al. (2021) Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discov 11: 2780-2795.
• Ran T, Eichmüller SB*, Schmidt P, and Schlander M* (2020) Reply to: Comments on "Cost of decentralized CAR T cell production in an academic non-profit setting". Int J Cancer, 148: 516-517. (Link to full text)
• Bozza M, De Roia A, Correia MP, Berger A, Tuch A, Schmidt A, Zörnig I, Jäger D, Schmidt P*, and Harbottle RP* (2021) A non-viral, non-integrating DNA Nanovector platform for the safe, rapid, and persistent manufacture of recombinant T Cells. Science Advances 7: eabf1333. (Link to full text)

• Hartmann L, Schröter P, Osen W, Baumann D, Offringa R, Moustafa M, Will R, Debus J, Brons S, Rieken S, and Eichmüller SB (2020) Photon versus carbon ion irradiation – immunomodulatory effects exerted on various murine tumor cell lines. Scientific Reports 10:21517. (Link to full text)
• Zhao X, Yang F, Mariz F, Osen W, Ottonello S, Bolchi A, and Müller M (2020) Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine. Plos Pathogens: 16:e1008827
• Ran T, Eichmüller SB*, Schmidt P, and Schlander M* (2020) Cost of decentralized CAR T cell production in an academic non-profit setting. Int J Cancer, 147: 3438-3445. (Link to full text)
• Busch E, Kubon KD, Mayer JKM, Pidelaserra-Martí G, Albert J, Hoyler B, Heidbuechel JPW, Stephenson KB, Lichty BD, Osen W, Eichmüller SB, Jäger D, Ungerechts G, and Engeland CE (2020) Measles vaccines designed for enhanced CD8+ T cell activation. Viruses 12:242. Link to full text.
• Hörhold F*, Eisel D*, Oswald M, Kolte A, Röll D, Osen W, Eichmüller SB, and König R (2020) Reprogramming of macrophages employing gene regulatory and metabolic network models. PLOS Computational Biology, in press. Link to full text.
• Schröter P, Hartmann L, Osen W, Baumann D, Offringa R, Eisel D, Debus J, Eichmüller SB*, and Rieken S* (2020) Radiation-induced alterations in immunogenicity of a murine pancreatic ductal adenocarcinoma cell line. Scientific Reports 10:686. Link to full text.

• Das K, Eisel D, Vormehr M, Müller-Decker K, Hommertgen A, Jäger D, Zörnig I, Feuerer M, Kopp-Schneider A, Osen W, and Eichmüller SB (2019) A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice. BMC Cancer 19:914. Link to full text
• Poos AM, Kordaß T, Kolte A, Ast V, Oswald M, Rippe K, and König R (2019) Applying MIPRIP 2.0: Modelling TERT regulation across 19 different cancer types. BMC Bioinformatics 20: 737.
• Katsanovskaja K, Driver T, Pipkorn R, and Edelson-Averbukh M (2019) Negative Ion Mode Collision-Induced Dissociation for Analysis of Protein Arginine Methylation. J Am Soc Mass Spectrom 30: 1229-1241.
• Gangkofner DS, Holzinger D, Schröder L, Eichmüller SB, Zörnig I, Jäger D, Wichmann G, Dietz A, Broglie MA, Herold-Mende C, Dyckhoff G, Boscolo-Rizzo P, Ezic J, Marienfeld RB, Möller P, Völkel G, Kraus J, Kestler H, Brunner C, Schuler PJ, Wigand M, Theodoraki MN, Döscher J, Hoffmann TK, Pawlita M, Waterboer T, and Laban S (2019) Patterns of antibody responses to non-viral cancer antigens in head and neck squamous cell carcinoma patients differ by Human papillomavirus status. Int J Cancer 145, 3436-3444.
• Laban S, Gangkofner DS, Holzinger D, Schroeder L, Eichmüller SB, Zörnig I, Jäger D, Wichmann G, Dietz A, Broglie MA, Herold-Mende C, Dyckhoff G, Boscolo-Rizzo P, Ezic RB, Marienfeld RB, Möller P, Völkel G, Kraus J, Kestler H, Brunner C, Schuler PJ, Wigand M, Theodoraki MN, Döscher J, Hoffmann TK, Pawlita M, Waterboer T, and Butt J (accepted) Antibody responses to cancer antigens identify patients with a poor prognosis among HPV-positive and HPV-negative head and neck squamous cell carcinoma patients. Clin Cancer Res 25: 7405-7412.
• Eisel D, Das K, Dickes E, König R, Osen W, and Eichmüller SB (2019) Cognate interaction with CD4+ T cells instructs tumor-associated macrophages to acquire M1-like phenotype. Front Immunol 10(219). Link to full text
• Sharbi-Yunger A, Grees M, Gal C, Bassan D, Eichmüller SB, Tzehoval E, Utikal J, Umansky V, and Eisenbach L (2019) A universal anti-cancer vaccine: chimeric invariant chain potentiates the inhibition of melanoma progression and improvement of survival. Int J Cancer 144: 909-921.

• Ast V*, Kordaß T*, Oswald M, Kolte A, Eisel D, Osen W, Eichmüller SB, Berndt A, and König R (2018) MiR-192, miR-200c and miR-17 are fibroblast-mediated inhibitors of colorectal cancer invasion. Oncotarget 9: 35559-35580. Link to full text
• Kordaß T, Weber CEM, Eisel D, Pane AA, Osen W, and Eichmüller SB (2018) miR‑193b and miR-30c-1* inhibit, whereas miR-576-5p enhances melanoma cell invasion. Oncotarget 9(65): 32507-32522. Link to full text
• Kordaß T, Osen W, and Eichmüller SB (2018) Controlling the immune suppressor: transcription factors and miRNAs regulating CD73/NT5E. Frontiers in Immunology, 9(813). Review. Link to full text
• Grees M, Sharbi-Yunger A, Evangelou C, Baumann D, Cafri G, Tzehoval E, Eichmüller SB, Offringa R, Utikal J, Eisenbach L, and Umansky V (2018) Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. Oncoimmunology 7(7): e1445457. Link to full text
• Michels J, Becker N, Suciu S, Kaiser I, Benner A, Kosaloglu-Yalcin Z, Agoussi S, Halama N, Pawlita M, Waterboer T, Eichmüller SB, Jäger D, Eggermont AMM, and Zörnig I (2018) Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC 18961 trial. Oncoimmunology 7: e1428157. Link to full text
  
• Krackhardt AM, Anliker B, Hildebrandt M, Bachmann M, Eichmüller SB, Nettelbeck DM, Renner M, Uharek L, Willimsky G, Schmitt M, Wels WS, and Schuessler-Lenz M (2018) Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies - the German Cancer Consortium approach. Cancer Immunol Immun 67(4):513-523. (request reprint)
• Lv N, Hao S, Luo C, Abukiwan A, Hao Y, Gai F, Huang W, Huang L, Xiao X, Eichmüller SB, and He D (2018) miR-137 inhibits melanoma cell proliferation through downregulation of GLO1. Sci China Life Sci 61: 541-549. Link to full text or request reprint

• Das K, Eisel D, Lenkl C, Goyal A, Diederichs S, Dickes E, Osen W, and Eichmüller SB (2017) Generation of murine β2-microglobulin deficient tumor cell lines using the CRISPR/Cas9 system. PLoS ONE 12: e0174077. Link to full text
• Eichmüller SB, Osen W, Mandelboim O, and Seliger B (2017) Immune modulatory microRNAs involved in tumor attack and tumor immune escape. J Natl Cancer Inst. Link to full text

• Weber CEM, Luo C, Hotz-Wagenblatt A, Gardyan A, Kordass T, Holland-Letz T, Osen W, and Eichmüller SB (2016) miR-339-3p is a tumor suppressor in melanoma. Cancer Res 76: 3562-3571. Link to full text.
• Werner S, Chen H, Butt J, Michel A, Knebel P, Holleczek B, Zörnig I, Eichmüller SB, Jäger D, Pawlita M, Waterboer T, and Brenner H (2016) Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. Scientific Reports 6: 25467. Link to full text.
  
• Veyhl-Wichmann M, Friedrich A, Vernaleken A, Singh S, Kipp H, Gorboulev V, Keller T, Chintalapati C, Pipkorn R, Pastor-Anglada M, Groll J, and Koepsell H (2016) Phosphorylation of RS1 (RSC1A1) Steers Inhibition of Different Exocytotic Pathways for Glucose Transporter SGLT1 and Nucleoside Transporter CNT1, and an RS1-Derived Peptide Inhibits Glucose Absorption. Mol Pharmacol 89: 118-132.
• Kordaß T, Weber CEM, Oswald M, Ast V, Bernhardt M, Novak D, Utikal J, Eichmüller SB, and König R (2016) SOX5 is involved in balanced MITF regulation in human melanoma cells. BMC Med Genomics 9: 10. Link to full text.
• Komljenovic D, Wiessler M, Waldeck W, Ehemann V, Pipkorn R, Schrenk HH, Debus J, and Braun K (2016) NIR-Cyanine Dye Linker: a Promising Candidate for Isochronic Fluorescence Imaging in Molecular Cancer Diagnostics and Therapy Monitoring. Theranostics 6: 131-141.
• Chen HD, Werner S, Butt J, Zörnig I, Knebel P, Michel A, Eichmüller SB, Jäger D, Waterboer T, Pawlita M, and Brenner H (2016) Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Oncotarget 7: 16420-32. Link to full text.

• Zörnig I, Halama N, Bermejo JL, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk C, Eichmüller SB*, and Jäger D* (2015) Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients. Int J Cancer 136: 138-151.
• Pfirschke C, Gebhardt C, Zörnig I, Pritsch M, Eichmüller SB, Jäger D, Enk A, and Beckhove P (2015) T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response. Cancer Immunol Immunother 64: 1369-1381.
• Lei J, Osen W, Gardyan A, Hotz-Wagenblatt A, Wei G, Gissmann L, Eichmüller S, and Loechelt M (2015) Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy. Plos One 10: e0138458.
• Hao S, Luo C, Abukiwan A, Wang G, He J, Huang L, Weber CEM, Lv N, Xiao X, Eichmüller SB, and He D (2015) miR-137 inhibits proliferation of melanoma cells by targeting PAK2. Exp Dermatol 24: 947-952.
• Gardyan A*, Osen W*, Zörnig I, Podola L, Agarwal M, Aulmann S, Ruggiero E, Schmidt M, Halama N, Leuchs B, von Kalle C, Beckhove P, Schneeweiss A, Jäger D, and Eichmüller SB (2015) Identification of NY-BR-1-specific CD4+ T cell epitopes using HLA-transgenic mice. Int J Cancer 136: 2588-2597.
• Amann PM, Czaja K, Bazhin AV, Rühl R, Eichmüller SB, Merk HF, and Baron JM (2015) LRAT overexpression diminishes intracellular levels of biologically active retinoids and reduces retinoid anti-tumor efficacy in the murine melanoma B16F10 cell line. Skin Pharmacol Physiol 28: 205-212.

• Schumacher T et al. (2014) A vaccine targeting mutant IDH1 induces antitumor immunity. Nature 512: 324-7.
• Schacht T et al. (2014) Estimating the activity of transcription factors by the effect on their target genes. Bioinformatics 30: i401-i7.
• Luo C et al. (2014) The role of microRNAs in melanoma. Eur J Cell Biol 93: 11-22.
• Amann PM et al. (2014) Knockdown of lecithin retinol acyltransferase increases all-trans retinoic acid levels and restores retinoid sensitivity in malignant melanoma cells. Exp Dermatol 23: 832-7.

• Simon-Keller K et al. (2013) Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholin receptor-redirected T cells. Am J Pathol 182: 2121-31.
• Luo C et al. (2013) miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J Invest Dermatol 133: 768-75.
• Luo C et al. (2013) MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Letters 341: 240-7.
• Hassel JC et al. (2013) Lecithin/retinol acyltransferase as a potential prognostic marker for malignant melanoma. Exp Dermatol 22: 757-9.

• Link to PubMed
• PDF file: publications Stefan Eichmüller (PDF | 158,89 KB)

• PDF file (PDF | 161,55 KB)

All reprints are available as PDF for personal use on request

• Contact for requesting PDF files